Bayer Schering Licenses Oncology Candidate To Molecular Insight
This article was originally published in The Pink Sheet Daily
Executive Summary
The Cambridge, Mass. biotech will develop the compound as a radiotherapeutic for malignant melanoma.
You may also be interested in...
Molecular Insight Acquires Novartis’ Onalta
Acquisition of the radiolabeled oncologic peptide is firm’s second deal in the past week.
Molecular Insight Acquires Novartis’ Onalta
Acquisition of the radiolabeled oncologic peptide is firm’s second deal in the past week.
AstraZeneca, Schering AG Partner On Developmental SERD Breast Cancer Drug
Collaboration will build on AstraZeneca’s expertise with Faslodex.